IP Library Granted Patent US 10,342,822
Granted Patent B2
US 10,342,822 · App. 15/788,558 · Granted Jul 9, 2019

Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system

Inventors: Nathan S. Bryan (Rockdale, TX); Jose G. Rocca (Doral, FL)
Assignees: Board of Regents of the University of Texas System; Neogenis Labs, Inc.
A61K33/00A61K9/0053A61K9/0056A61K9/20A61K9/2009A61K9/2013A61K31/195A61K31/198A61K31/375A61K31/714A61K36/21A61K36/734A61K38/44A61K45/06C12Y107/02001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,342,822
App. No.
15/788,558
Granted
Jul 9, 2019
Kind
B2
Abstract

A composition and method of providing nitric oxide and nitrite therapy to patients whereby a therapeutic amount is bioavailable within approximately 30 minutes of administration. In embodiments of the invention, nitric oxide is produced in the oral cavity.

Claims (17)

1. A delivery system comprising:

at least one nitric oxide-producing component; and

a dispersable medium adapted to be consumed in the oral cavity;

wherein the nitric oxide-producing component is adapted to generate nitric oxide in vivo upon consumption of the dispersable medium, wherein the nitric oxide-producing component comprises about 1 mg to about 150 mg of a nitrite salt and about 10 mg to about 10,000 mg of nitrite reductase, wherein the delivery system is an oral composition and wherein the oral composition comprises about 1,000 mg to about 10,000 mg of beet root in powder form.

2. The delivery system of claim 1 , wherein the dispersable medium is dissolvable in the oral cavity.

3. The delivery system of claim 1 , wherein the delivery system is adapted to generate nitric oxide in the oral cavity.

4. The delivery system of claim 1 , where the nitric oxide-producing component is adapted to generate nitric oxide in-vivo in response to dissolution of the delivery system in the gastro intestinal tract.

5. The delivery system of claim 1 , wherein the delivery system is formed of a lozenge, liquid, powder, solid, semi-solid, cream, gel, emulsion, suspension, heterogenic liquid, film, or topical.

6. The delivery system of claim 1 , wherein the dispersable medium comprises one or more of a sugar, dispersing agent, flavor, sweetener, color, alcohol, maltodextren, or filler.

7. The delivery system of claim 1 further comprising a barrier for preventing contact of two or more species of the nitric oxide-producing component.

8. The delivery system of claim 7 , wherein the two or more species are nitrite and nitrite reductase.

9. The delivery system of claim 7 , wherein the barrier comprises a sugar, dispersing agent, flavors, sweetener, color, alcohol, maltodextren, or filler.

10. The delivery system of claim 1 further comprising a disintegrating agent, a compactible excipient, or both.

11. The delivery system of claim 10 , wherein the disintegrating agent absorbs fluid upon contact with fluid.

12. The delivery system of claim 10 , wherein the compactable excipient is adapted to maintain the delivery system in a compressed form.

13. The delivery system of claim 10 , wherein the compactable excipient is chemically inert, does not absorb fluid, is non-hydroscopic, protects water-sensitive nitric oxide-producing components, does not react with nitric oxide-producing components and/or has a narrow particle size distribution.

14. The delivery system of claim 10 wherein the disintegrating agent causes the compactable excipient to break apart upon expansion.

Assignments (4)
CHANGE OF NAME Recorded Jun 9, 2022
From: NEOGENIS LABORATORIES, INC.
To: HUMAN POWER OF N COMPANY
Reel/Frame 060329/0196 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 043907 FRAME: 0866. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Apr 4, 2022
From: ROCCA, JOSE G.
To: NEOGENIS LABORATORIES, INC.
Reel/Frame 060120/0434 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2017
From: BRYAN, NATHAN S.
To: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 043907/0562 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2017
From: ROCCA, JOSE G.
To: NEOGENIS LABS, INC.
Reel/Frame 043907/0866 →
Continuity (5)
Continuation 14989714 · Jan 6, 2016
Continuation 13588211 · Aug 17, 2012
Continuation In Part 12484364 · Jun 15, 2009
Provisional Application 61524539 · Aug 17, 2011
Related Publication 20180153929A1 · Jun 7, 2018